Stockreport

Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]

Pharvaris N.V. - Ordinary Shares  (PHVS) 
PDF Timeline for submission of NDA dossier of deucrictibant IR for on-demand treatment of HAE attacks remains on-track in 1H2026 Enrollment ongoing in CREAATE, a pivotal [Read more]